Results 41 to 50 of about 13,851 (214)

Osteocytic sclerostin expression as an indicator of altered bone turnover [PDF]

, 2023
: Renal osteodystrophy (ROD) is a complex and serious complication of chronic kidney disease (CKD), a major global health problem caused by loss of renal function.
Etienne Cavalier, Wim Van Hul, Van Hul, Wim, d' Haese, Patrick C., Cavalier, Etienne, Geert Dams, Verhulst, Anja, Dams, Geert, Yentl Huybrechts, Mathias Haarhaus, Huybrechts, Yentl, D'Haese, Patrick C, Anja Verhulst, Haarhaus, Mathias, Pieter Evenepoel, Patrick C. D’Haese, D'Haese, Patrick C.C., Evenepoel, Pieter, Evenepoel, P, Cavalier, E, Van, Hul W, Huybrechts, Y, D’Haese, Patrick C., Dams, G, D'Haese, PCC, Haarhaus, M, Verhulst, A   +26 more
core   +1 more source

The sclerostin-neutralizing antibody AbD09097 recognizes an epitope adjacent to sclerostin's binding site for the Wnt co-receptor LRP6 [PDF]

Open Biology, 2016
The glycoprotein sclerostin has been identified as a negative regulator of bone growth. It exerts its function by interacting with the Wnt co-receptor LRP5/6, blocks the binding of Wnt factors and thereby inhibits Wnt signalling.
V. Boschert, C. Frisch, J. W. Back, K. van Pee, S. E. Weidauer, E.-M. Muth, P. Schmieder, M. Beerbaum, A. Knappik, P. Timmerman, T. D. Mueller   +10 more
doaj   +1 more source

Sclerostin as a novel marker of bone turnover in athletes

, 2016
Sclerostin is a protein secreted by osteocytes that acts as an inhibitor of bone formation. It has been shown that physical activity affects sclerostin concentration and thus bone remodelling.
M Majda, M Słowińska-Lisowska, P Jóźków, M Mędraś, A Zagrodna   +4 more
core   +1 more source

Sclerostin inhibition in rare bone diseases: Molecular understanding and therapeutic perspectives

Journal of Orthopaedic Translation
Sclerostin emerges as a novel target for bone anabolic therapy in bone diseases. Osteogenesis imperfecta (OI) and X-linked hypophosphatemia (XLH) are rare bone diseases in which therapeutic potential of sclerostin inhibition cannot be ignored.
Tao Xiaohui, Luyao Wang, Xin Yang, Hewen Jiang, Ning Zhang, Huarui Zhang, Dijie Li, Xiaofei Li, Yihao Zhang, Shenghang Wang, Chuanxin Zhong, Sifan Yu, Meishen Ren, Meiheng Sun, Nanxi Li, Tienan Chen, Yuan Ma, Fangfei Li, Jin Liu, Yuanyuan Yu, Hua Yue, Zhenlin Zhang, Ge Zhang   +22 more
doaj   +1 more source

The association of circulating sclerostin level with markers of bone metabolism in patients with thyroid dysfunction [PDF]

Journal of Medical Biochemistry, 2020
Background: The aim of this study was to compare serum sclerostin concentrations in patients with thyroid dysfunction with euthyroid control subjects and to assess the relationship between sclerostin and markers of bone metabolism (osteocalcin and beta ...
Mihaljević Olgica, Živančević-Simonović Snežana, Lučić-Tomić Aleksandra, Živković Irena, Minić Rajna, Mijatović-Teodorović Ljiljana, Jovanović Zorica, Anđelković Marija, Stanojević-Pirković Marijana   +8 more
doaj  

Sclerostin as Regulatory Molecule in Vascular Media Calcification and the Bone–Vascular Axis

Toxins, 2019
Sclerostin is a well-known inhibitor of bone formation that acts on Wnt/β-catenin signaling. This manuscript considers the possible role of sclerostin in vascular calcification, a process that shares many similarities with physiological bone ...
Annelies De Maré, Stuart Maudsley, Abdelkrim Azmi, Jhana O. Hendrickx, Britt Opdebeeck, Ellen Neven, Patrick C D’Haese, Anja Verhulst   +7 more
doaj   +1 more source

Wnt signaling pathway inhibitors, sclerostin and DKK-1, correlate with pain and bone pathology in patients with Gaucher disease

Frontiers in Endocrinology, 2022
Patients with Gaucher disease (GD) have progressive bone involvement that clinically presents with debilitating bone pain, structural bone changes, bone marrow infiltration (BMI), Erlenmeyer (EM) flask deformity, and osteoporosis. Pain is referred by the
Margarita M. Ivanova, Julia Dao, Neil Kasaci, Andrew Friedman, Lauren Noll, Ozlem Goker-Alpan   +5 more
doaj   +1 more source

Association of total and bioactive serum sclerostin levels with bone metabolism in type 2 diabetes mellitus

Journal of Clinical & Translational Endocrinology
Background: Sclerostin has been associated with decreased bone turnover in patients with type 2 diabetes mellitus (T2DM). The relationship with bone turnover markers (BTMs) and bone mineral density (BMD) remains unclear.
Cyril Traechslin, Lilian Sewing, Sandra Baumann, Leticia Grize, Janina Vavanikunnel, Marius Kraenzlin, Christoph Henzen, Christian Meier   +7 more
doaj   +1 more source

Bone Sclerostin and Dickkopf-related protein-1 are positively correlated with bone mineral density, bone microarchitecture, and bone strength in postmenopausal osteoporosis

BMC Musculoskeletal Disorders, 2021
Background Wnt-catenin signaling antagonists sclerostin and dickkopf-related protein-1 (Dkk-1) inhibit bone formation and are involved in the pathogenesis of postmenopausal osteoporosis (PO). However, the association between sclerostin and Dkk-1 and bone
Jia Peng, Zhang Dong, Zhang Hui, Wang Aifei, Deng Lianfu, Xu Youjia   +5 more
doaj   +1 more source

Novel actions of sclerostin on bone [PDF]

Journal of Molecular Endocrinology, 2019
The discovery that two rare autosomal recessive high bone mass conditions were caused by the loss of sclerostin expression prompted studies into its role in bone homeostasis. In this article, we aim to bring together the wealth of information relating to sclerostin in bone though discussion of rare human disorders in which sclerostin is reduced or ...
Gill, Holdsworth, Scott J, Roberts, Hua Zhu, Ke   +2 more
openaire   +2 more sources